Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myelogenous Leukemia
U.S. FDA grants orphan drug designation for Troxatyl
June 6th, 2005
Structural GenomiX, Inc., (SGX) announced that it has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, Troxatyl (troxacitabine), for the treatment of acute myelogenous leukemia (AML). Troxatyl is a novel nucleoside analog that is currently being evaluated by the company in a phase I/II trial for the treatment of relapsed AML and in a phase I/II trial for the treatment of various solid tumors. The company plans to complete the phase I/II AML trial and progress Troxatyl into a phase II trial in relapsed and/or refractory adult AML patients in mid-2005. Over 600 patients have received...
Source: Biotech Business Week (2005-06-06)
|
